| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | REPLIGEN CORPORATION |
| Entity Central Index Key | 0000730272 |
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | PAY VERSUS PERFORMANCE As required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection A ct and S-K, S-K) “Compensation Discussion and Analysis – Compensation Objectives” Pay Versus Performance Table Value of Initial Fixed $100 Year Summary Compensation (1) Average Non-PEO Average Non-PEO (2) Total (3) Peer Group (4) Net Income (5) Adjusted (6) 2022 7,713,930 (14,037,928 ) 2,030,204 (7) 373,690 (7) 183 111 185,958,784 823,421,806 2021 7,765,070 28,761,887 1,903,210 (7) 3,095,727 (7) 286 125 128,290,831 666,832,455 2020 5,066,061 36,587,864 1,660,855 (8) 4,883,849 (8) 207 126 59,925,688 360,009,590 (1) The amounts reported represent the “compensation actually paid” to Mr. Hunt, computed in accordance with Item 402(v) of Regulation S-K, S-K, Year Summary Compensation Summary Compensation (a) Equity Award (b) Compensation Actually 2022 7,713,930 (6,123,490 ) (15,628,368 ) (14,037,928 ) 2021 7,765,070 (5,663,515 ) 26,660,332 28,761,887 2020 5,066,061 (3,957,311 ) 35,479,114 36,587,864 (a) The amounts reported represent the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns of the Summary Compensation Table for the applicable year. (b) The amounts deducted or added in calculating the equity award adjustments are as follows and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of the grant: Year Year End Fair Year Over Fair Value as of Year Over Year Fair Value at the Value of Total Equity 2022 5,089,051 (16,700,137 ) — (4,017,282 ) — — (15,628,368 ) 2021 5,871,874 18,454,854 — 2,333,604 — — 26,660,332 2020 8,611,644 27,291,322 — (423,852 ) — — 35,479,114 (2) The amounts reported represent the average “compensation actually paid” to the NEOs other than Mr. Hunt as a group, computed in accordance with Item 402(v) of Regulation S-K. S-K, Year Average Reported Summary Non-PEO Average Summary (a) Average Equity Award (b) Average Compensation Non-PEO 2022 2,030,204 (1,293,539 ) (362,975 ) 373,690 2021 1,903,210 (1,158,499 ) 2,351,016 3,095,727 2020 1,660,855 (991,336 ) 4,214,330 4,883,849 (a) The amounts reported represent the average of the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable fiscal year. (b) The amounts deducted or added in calculating for equity award adjustments are as follows: Year Year End Fair Year Over Fair Value as of Year Over Year Fair Value at the Value of Total Equity 2022 972,047 (895,955 ) — (426,369 ) (12,698 ) — (362,975 ) 2021 1,240,869 923,948 — 186,199 — — 2,351,016 2020 2,164,711 1,959,514 — 90,105 — — 4,214,330 (3) Total shareholder return (“TSR”) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. (4) Represents the weighted peer group TSR. The peer group used for this purpose is the Nasdaq Biotechnology Index, a published industry index. (5) The dollar amounts reported represent the amount of net income reflected in the Company’s audited financial statements for the applicable fiscal year. (6) Adjusted revenue is defined as the Company’s total consolidated revenue as reported under U.S. GAAP adjusted to reflect the impact of acquisitions. In 2022, there was a $21.9 million favorable impact on total as-reported as-reported as-reported non-financial (7) Non-PEO (8) Non-PEO | ||
| Company Selected Measure Name | Adjusted revenue | ||
| Named Executive Officers, Footnote [Text Block] | Non-PEO | Non-PEO | Non-PEO |
| Peer Group Issuers, Footnote [Text Block] | Represents the weighted peer group TSR. The peer group used for this purpose is the Nasdaq Biotechnology Index, a published industry index. | ||
| PEO Total Compensation Amount | $ 7,713,930 | $ 7,765,070 | $ 5,066,061 |
| PEO Actually Paid Compensation Amount | $ (14,037,928) | 28,761,887 | 36,587,864 |
| Adjustment To PEO Compensation, Footnote [Text Block] | (1) The amounts reported represent the “compensation actually paid” to Mr. Hunt, computed in accordance with Item 402(v) of Regulation S-K, S-K, Year Summary Compensation Summary Compensation (a) Equity Award (b) Compensation Actually 2022 7,713,930 (6,123,490 ) (15,628,368 ) (14,037,928 ) 2021 7,765,070 (5,663,515 ) 26,660,332 28,761,887 2020 5,066,061 (3,957,311 ) 35,479,114 36,587,864 (a) The amounts reported represent the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns of the Summary Compensation Table for the applicable year. (b) The amounts deducted or added in calculating the equity award adjustments are as follows and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of the grant: Year Year End Fair Year Over Fair Value as of Year Over Year Fair Value at the Value of Total Equity 2022 5,089,051 (16,700,137 ) — (4,017,282 ) — — (15,628,368 ) 2021 5,871,874 18,454,854 — 2,333,604 — — 26,660,332 2020 8,611,644 27,291,322 — (423,852 ) — — 35,479,114 | ||
| Non-PEO NEO Average Total Compensation Amount | $ 2,030,204 | 1,903,210 | 1,660,855 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 373,690 | 3,095,727 | 4,883,849 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (2) The amounts reported represent the average “compensation actually paid” to the NEOs other than Mr. Hunt as a group, computed in accordance with Item 402(v) of Regulation S-K. S-K, Year Average Reported Summary Non-PEO Average Summary (a) Average Equity Award (b) Average Compensation Non-PEO 2022 2,030,204 (1,293,539 ) (362,975 ) 373,690 2021 1,903,210 (1,158,499 ) 2,351,016 3,095,727 2020 1,660,855 (991,336 ) 4,214,330 4,883,849 (a) The amounts reported represent the average of the sum of the amounts reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable fiscal year. (b) The amounts deducted or added in calculating for equity award adjustments are as follows: Year Year End Fair Year Over Fair Value as of Year Over Year Fair Value at the Value of Total Equity 2022 972,047 (895,955 ) — (426,369 ) (12,698 ) — (362,975 ) 2021 1,240,869 923,948 — 186,199 — — 2,351,016 2020 2,164,711 1,959,514 — 90,105 — — 4,214,330 | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Compensation Actually Paid and Company TSR The graph below describes the relationship between compensation actually paid to Mr. Hunt and the average compensation actually paid to the Company’s other NEOs to the Company’s TSR over the three-year period from December 31, 2019 to December 31, 2022, assuming an initial investment of $100 on December 31, 2019. As the graph shows, this relationship is generally aligned in large part because a significant portion of the compensation actually paid to the Company’s NEOs is in the form of equity awards, the value of which is impacted by the stock price changes. | ||
| Compensation Actually Paid vs. Net Income [Text Block] | Compensation Actually Paid and Net Income The graph below shows the relationship between compensation actually paid to Mr. Hunt and the average compensation actually paid to the Company’s other NEOs to the Company’s net income for the three years presented in the Pay Versus Performance Table. The Company does not use net income as a performance measure in its executive compensation program: | ||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | Compensation Actually Paid and Adjusted Revenue The graph below shows the relationship between compensation actually paid to Mr. Hunt and the average non-financial | ||
| Total Shareholder Return Vs Peer Group [Text Block] | Total Shareholder Return The graph below describes the relationship between Repligen Corporation’s (Nasdaq:RGEN) TSR and the TSR for the Nasdaq Biotechnology index: | ||
| Tabular List [Table Text Block] | Tabular List of Performance Measures The following table includes financial performance measures that the Company has determined are its most Financial Measure Application in Most Recently Adjusted revenue Annual Cash Incentive Compensation – Corporate Objectives Adjusted EPS Annual Cash Incentive Compensation – Corporate Objectives Adjusted ROIC Long-term Incentive Plan – PSU Portion (3-year Base Organic Growth Long-term Incentive Plan – PSU Portion (3-year | ||
| Total Shareholder Return Amount | $ 183 | 286 | 207 |
| Peer Group Total Shareholder Return Amount | 111 | 125 | 126 |
| Net Income (Loss) | $ 185,958,784 | $ 128,290,831 | $ 59,925,688 |
| Company Selected Measure Amount | 823,421,806 | 666,832,455 | 360,009,590 |
| PEO Name | Mr. Hunt | Mr. Hunt | Mr. Hunt |
| Additional 402(v) Disclosure [Text Block] | Description of Relationship Between Compensation Actually Paid and Selected Performance Metrics “Compensation and Discussion Analysis – Compensation Objectives” S-K, S-K, | ||
| Total Company Selected Measure Amount | 670,500,000 | 366,300,000 | |
| Company Selected Measure Amount Adjusted (Decreased) | 3,700,000 | 6,300,000 | |
| Impact on Consolidated Revenue | 21,900,000 | ||
| Total Company Selected Measure Amount Related to Change in Foreign Exchange Rate | 801,500,000 | ||
| Measure [Axis]: 1 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Adjusted revenue | ||
| Measure [Axis]: 2 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Adjusted EPS | ||
| Measure [Axis]: 3 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Adjusted ROIC | ||
| Measure [Axis]: 4 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Base Organic Growth | ||
| PEO [Member] | Value of Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (6,123,490) | $ (5,663,515) | $ (3,957,311) |
| PEO [Member] | Equity Award Adjustments [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (15,628,368) | 26,660,332 | 35,479,114 |
| Fair Value of Equity Awards | 5,089,051 | 5,871,874 | 8,611,644 |
| Change in Fair Value of Outstanding and Unvested Equity Awards | (16,700,137) | 18,454,854 | 27,291,322 |
| Fair Value Equity Awards Granted and Vested | 0 | 0 | 0 |
| Change in Fair Value of Equity Awards Granted, Vested | (4,017,282) | 2,333,604 | (423,852) |
| Fair Value of Equity Awards that Failed to Meet Vesting Conditions | 0 | 0 | 0 |
| Value of Dividends or Other Earnings Paid on Stock or Option Awards | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Value of Equity Awards [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (1,293,539) | (1,158,499) | (991,336) |
| Non-PEO NEO [Member] | Equity Award Adjustments [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (362,975) | 2,351,016 | 4,214,330 |
| Fair Value of Equity Awards | 972,047 | 1,240,869 | 2,164,711 |
| Change in Fair Value of Outstanding and Unvested Equity Awards | (895,955) | 923,948 | 1,959,514 |
| Fair Value Equity Awards Granted and Vested | 0 | 0 | 0 |
| Change in Fair Value of Equity Awards Granted, Vested | (426,369) | 186,199 | 90,105 |
| Fair Value of Equity Awards that Failed to Meet Vesting Conditions | (12,698) | 0 | 0 |
| Value of Dividends or Other Earnings Paid on Stock or Option Awards | $ 0 | $ 0 | $ 0 |
